Skip to main content
Premium Trial:

Request an Annual Quote

Arcis Biotechnology, Andrew Alliance Ink Comarketing Pact

NEW YORK (GenomeWeb) — Arcis Biotechnology and Andrew Alliance announced today that they have signed an agreement to comarket their respective technologies for automated nucleic acid stabilization and preparation.

Under the terms of the deal, the partners will promote the use of Arcis' reagents for DNA and RNA preparation with Andrew Alliance platforms, including the Andrew+ pipetting robot, and its OneLab lab protocol design and execution software.

Additional terms were not disclosed.

"Our agreement with Arcis will support our customers using a single platform to not only complete sample preparation, but also prepare for downstream analysis," Piero Zucchelli, CEO of Geneva-based Andrew Alliance, said in a statement.

In October, UK-based Arcis signed an agreement under which its nucleic acid sample prep chemistry is being used by Teleflex in the development of a rapid diagnostic assay.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.